Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Jun;128(6):781-5.

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

B V Jegasothy  1 , C D Ackerman, S Todo, J J Fung, K Abu-Elmagd, T E Starzl
Affiliations

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

B V Jegasothy et al. Arch Dermatol. 1992 Jun.

Abstract

Background: Psoriasis, a disease of unknown etiology, is in some patients severe, extremely debilitating, and unresponsive to conventional therapies, including UV-B, oral psoralen with long-wave UV radiation in the A range (PUVA), oral retinoids, and methotrexate. We report the results from our study of seven patients with refractory psoriasis who were treated with the new immunosuppressive drug, tacrolimus (FK 506).

Observations: All seven patients showed a dramatic resolution of psoriasis that remained in remission as long as they received full-dose therapy. Serial skin biopsy specimens demonstrated a rapid disappearance of the inflammatory infiltrate and a slower resolution of the epidermal changes. Tacrolimus was well tolerated during the 5.5 to 14 months of observation. Side effects, including nephrotoxicity and hypertension, were controlled by appropriate modification of drug dosage.

Conclusions: Tacrolimus, a new immunosuppressive agent, is effective in treating patients with severe recalcitrant psoriasis. The mechanism of its action in psoriasis is unknown, but it may be related to its ability to modulate immune function. Further studies will establish criteria for patient selection and drug dosage, to maximize efficacy of this agent in psoriasis, while minimizing its toxicity.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Left, Generalized erythrodermic psoriasis in patient 5 before tacrolimus (FK 506) treatment; right, complete resolution after 3 weeks of tacrolimus treatment.
Fig 2
Fig 2
Left, Histopathologic findings of patient in Fig 1 showing typical changes of psoriasis before tacrolimus (FK 506) treatment; right, 2 weeks later. Note persistence of epidermal acanthosis, but almost complete resolution of dermal and epidermal inflammation (hematoxylin-eosin, X100).
See this image and copyright information in PMC

References

    1. Krueger JG, Krane JF, Carter M, Gottlieb A. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol. 1990;94(suppl):1355–1405. - PubMed
    1. Basdsgaard O, Gupta A, Taylor S, Ellis C, Voorhees J, Cooper K. Psoriatic epidermal cells demonstrate increased numbers and function on non-Langerhans antigen presenting cells. J Invest Dermatol. 1989;92:190–195. - PubMed
    1. Müeller W, Hermann B. Cyclosporine A for psoriasis. N Engl J Med. 1979;301:555. - PubMed
    1. Ellis CN, Gorsulowsky DC, Hamilton T. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110–3116. - PubMed
    1. Powles AV, Baker BS, Valdimarsson H, Holme B, Fry L. Four years of experience with cyclosporine A for psoriasis. Br J Dermatol. 1990;122 (suppl 36):13–19. - PubMed

Publication types